Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, Others); By Region, And Segment Forecasts, 2023 - 2032

Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, Others); By Region, And Segment Forecasts, 2023 - 2032

The global aptamers market size is expected to reach USD 16.33 billion by 2032, according to a new study by Polaris Market Research. The report “Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, and Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, and Others); By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Versatility of aptamers and their potential applications in various industries such as healthcare, biotechnology, and diagnostics have attracted the attention of many companies. Moreover, the availability of customized aptamers for specific targets has expanded the applications of aptamers beyond their traditional use in research and diagnostics. This has led to the development of new aptamer-based products, including therapeutics and biosensors, which are expected to further drive the growth of the aptamers market.

The SELEX technology has been used to develop aptamers that can bind to specific biomarkers related to SARS-CoV-2 and COVID-19, allowing for the development of diagnostic kits and assays. These aptamer-based diagnostic tools can provide high sensitivity and specificity in detecting the virus and related biomarkers, which can aid in disease diagnosis and monitoring. As a result, the introduction of such diagnostic kits and assays in the market is expected to drive the growth of the market.

In December 2021, Achiko AG's Aptamex, a COVID-19 diagnostic kit, received approval from the health ministry of Indonesia. Aptamex is a 2nd generation kit developed using DNA aptamer technology, which is cost-effective, chemically synthesized, diagnostic kit in the pharmaceuticals.

Market growth is further supported by various regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, & CDSCO, which have taken initiatives to support the research and development in this field. For example, in March 2020, the U.S. FDA granted Fast Track designation to IVERIC Bio’s Zimura for the treatment of patients with geographic atrophy (GA) secondary to AMD. It is a pegylated RNA aptamer, which is synthesized & administered by the intra-vitreal injection. It works by the inhibition of factor C5, considered responsible for onset of AMD.

Aptamers Market Report Highlights

Nucleic acid segment dominated the market, owing to rapid development in the diagnostics, therapeutics, and advancements in the biomarker discovery

R&D segment accounted for the larger market share, as there is a strong interest in aptamer manufacturing companies, and favorable government initiatives

Diagnostic segment recorded fastest growth rate, owing to rising need for aptamer based diagnostic kits for the early disease diagnosis

North America garnered the largest share, owing to the presence of companies engaged in the development of aptamers, and strong industry academia collaboration for scientific breakthroughs

Asia Pacific is projected to register a higher growth rate, owing to the presence of large patient pool, huge untapped population, and favorable government policies for research.

The global players include Base Pair Biotechnologies, SomaLogic, Aptadel Therapeutics, Aptamer Group, Noxxon Pharma, Aptagen, TriLink Biotechnologies, Altermune, Vivonics, and AM Biotechnologies.

Polaris Market Research has segmented the aptamers market report based on type, application, and region:

Aptamers, Type Outlook (Revenue - USD Billion, 2019 - 2032)

Nucleic Acid Aptamer

Peptide Aptamer

Aptamers, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Diagnostics

Therapeutics

Research and Development

Others

Aptamers, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa